Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms by Site 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Recurrence 1Neoplasms 1Neoplasm Metastasis 1Lung Diseases 1Lethal Congenital Contracture Syndrome 2 1Head and Neck Neoplasms 1Fibromatosis, Gingival, 2 1Carcinoma, Squamous Cell 1Carcinoma 1Bronchial Neoplasms 1Breast Neoplasms 1

Interventions

zenocutuzumab 2seribantumab 2pembrolizumab 1patritumab 1osimertinib 1exemestane 1cemiplimab 1Vinorelbine 1Vascular Endothelial Growth Factor A 1Trastuzumab 1Paroxetine 1Paclitaxel 1Letrozole 1Itraconazole 1Fulvestrant 1Erlotinib Hydrochloride 1Docetaxel 1Carboplatin 1Antibodies, Bispecific 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lethal Congenital Contracture Syndrome 2 × patritumab × Clear all
NCT00730470 2010-07-29

Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors

U3 Pharma GmbH

Phase 1 Completed
60 enrolled

Lethal Congenital Contracture Syndrome 2, Fibromatosis, Gingival, 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡